Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient, treatment, and tumor-related characteristics of all stage IV IBC patients per breast cancer subtype (n = 744)

From: Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer

  HR+/HER2−
(n = 340)
HR+/HER2+
(n = 131)
HR−/HER2+ (n = 148) HR−/HER2−
(n = 125)
p value
  N (%) N (%) N (%) N (%)  
Age, median (IQR) 61 (52–73) 60 (50–74) 57.5 (50–69) 62 (52–73) 0.191
Histological grade
 1 6 (1.8) 2 (1.5) 0 (0.0) 1 (0.8) NC
 2 40 (11.8) 13 (9.9) 16 (10.8) 8 (6.4)
 3 44 (12.9) 19 (14.5) 36 (24.3) 37 (29.6)
 Unknown* 250 (73.5) 97 (74.1) 96 (64.9) 79 (63.2)  
Histological type
 Ductal 279 (82.1) 119 (90.8) 113 (89.9) 110 (80.0) 0.019
 Lobular 49 (14.4) 7 (5.3) 10 (6.7) 8 (6.4)
 Other 12 (3.5) 5 (3.8) 5 (3.4) 7 (5.6)
Metastatic sites
 1 167 (49.1) 54 (41.2) 74 (50.0) 58 (46.4)  
 2 or more 173 (50.9) 77 (58.8) 74 (50.0) 67 (53.6) 0.414
Surgery
 Yes 60 (17.7) 24 (18.3) 40 (27.0) 25 (20.0) 0.113
 No 280 (82.4) 107 (81.7) 108 (73.0) 100 (80.0)
ALND
 Yes 46 (13.5) 14 (10.7) 24 (16.2) 18 (14.4) 0.603
 No 294 (86.5) 117 (89.3) 124 (83.8) 107 (85.6)
Chemotherapy
 Yes 166 (48.8) 88 (67.2) 128 (86.5) 103 (82.4) < 0.001
 No 174 (51.2) 43 (32.8) 20 (13.5) 22 (17.6)
Endocrine therapy
 Yes 253 (74.4) 83 (63.4) 6 (4.1) 2 (1.6) < 0.001
 No 87 (25.6) 48 (36.6) 142 (96.0) 123 (98.4)
Radiation therapy
 Yes 65 (19.1) 21 (16.0) 28 (18.9) 31 (24.8) 0.347
 No 275 (80.9) 110 (84.0) 120 (81.1) 94 (75.2)
Anti-HER2 therapy
 Yes 21 (6.2) 90 (68.7) 111 (75.0) 11 (8.8) < 0.001
 No 319 (93.8) 41 (31.3) 37 (25.0) 114 (91.2)
Trimodality therapy
 Yes 30 (8.8) 7 (5.3) 14 (9.5) 9 (7.2) 0.555
 No 310 (91.2) 124 (94.7) 134 (90.5) 116 (92.8)
  1. p values indicated in italics are considered as statistically significant (p < 0.05). Abbreviations: IQR interquartile range, ALND axillary lymph node dissection, HR hormone receptor, HER2 human epidermal growth factor receptor-2, NC not calculable.*Histological grade is usually determined postoperatively, and since most patients are not treated with surgery, this variable is unknown in most of the patients. Trimodality therapy: neoadjuvant chemotherapy, surgery, radiation therapy